Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma (original) (raw)

• Schubbert, S., Shannon, K. & Bollag, G. Hyperactive Ras in developmental disorders and cancer. Nat. Rev. CancerNatl. Rev. 7, 295–308 (2007).
  Article CAS Google Scholar
• Jakob, J.A. et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118, 4013–4023 (2011).
  Google Scholar
• Flaherty, K.T. et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N. Engl. J. Med. 363, 809–819 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Gilmartin, A.G. et al. GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition. Clin. Cancer Res. 17, 989–1000 (2011).
  Article CAS PubMed Google Scholar
• Bollag, G. et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467, 596–599 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Flaherty, K.T. et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. New Engl. J. Med. 367, 107–114 (2012).
  Article CAS PubMed Google Scholar
• Falchook, G.S. et al. Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol. 13, 782–789 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Kirkwood, J.M. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin. Cancer Res. 18, 555–567 (2012).
  Article CAS PubMed Google Scholar
• Ascierto, P.A. et al. Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J. Clin. Oncol. 30, suppl; abstr 8511 (2012).
  Google Scholar
• Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431–435 (2010).
  Article CAS PubMed Google Scholar
• Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427–430 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Heidorn, S.J. et al. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF. Cell 140, 209–221 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Su, F. et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N. Engl. J. Med. 366, 207–215 (2012).
  Article CAS PubMed PubMed Central Google Scholar
• Villanueva, J. et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18, 683–695 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Paraiso, K.H. et al. Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy. Br. J. Cancer 102, 1724–1730 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Morris, M.K., Saez-Rodriguez, J., Sorger, P.K. & Lauffenburger, D.A. Logic-based models for the analysis of cell signaling networks. Biochemistry 49, 3216–3224 (2010).
  Article CAS PubMed Google Scholar
• Sachs, K., Gifford, D., Jaakkola, T., Sorger, P. & Lauffenburger, D.A. Bayesian network approach to cell signaling pathway modeling. Sci. STKE 2002, pe38 (2002).
  PubMed Google Scholar
• Della Gatta, G. et al. Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL. Nat. Med 18, 436–440 (2012).
  Article CAS PubMed Google Scholar
• Belcastro, V. et al. Transcriptional gene network inference from a massive dataset elucidates transcriptome organization and gene function. Nucleic Acids Res. 39, 8677–8688 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999).
  Article CAS PubMed Google Scholar
• Yeh, T.C. et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin. Cancer Res. 13, 1576–1583 (2007).
  Article CAS PubMed Google Scholar
• Solit, D.B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006).
  Article CAS PubMed Google Scholar
• Pratilas, C.A. et al. (V600E)BRAF is associated with disabled feedback inhibition of RAF-MEK signaling and elevated transcriptional output of the pathway. Proc. Natl. Acad. Sci. USA 106, 4519–4524 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545–15550 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Luo, J. et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137, 835–848 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• VanBrocklin, M.W., Verhaegen, M., Soengas, M.S. & Holmen, S.L. Mitogen-activated protein kinase inhibition induces translocation of Bmf to promote apoptosis in melanoma. Cancer Res. 69, 1985–1994 (2009).
  Article CAS PubMed PubMed Central Google Scholar
• Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics 27, 1739–1740 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Fry, D.W. et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427–1438 (2004).
  CAS PubMed Google Scholar
• Shapiro, G.I. Cyclin-dependent kinase pathways as targets for cancer treatment. J. Clin. Oncol. 24, 1770–1783 (2006).
  Article CAS PubMed Google Scholar
• Lens, S.M., Voest, E.E. & Medema, R.H. Shared and separate functions of polo-like kinases and aurora kinases in cancer. Nat. Rev. CancerNatl. Rev. 10, 825–841 (2010).
  Article CAS Google Scholar
• Joseph, E.W. et al. The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner. Proc. Natl. Acad. Sci. USA 107, 14903–14908 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Packer, L.M., East, P., Reis-Filho, J.S. & Marais, R. Identification of direct transcriptional targets of (V600E)BRAF/MEK signalling in melanoma. Pigment Cell Melanoma Res. 22, 785–798 (2009).
  Article CAS PubMed Google Scholar
• Hoeflich, K.P. et al. Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 69, 3042–3051 (2009).
  Article CAS PubMed Google Scholar
• Dry, J.R. et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264–2273 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Puyol, M. et al. A synthetic lethal interaction between K-Ras oncogenes and Cdk4 unveils a therapeutic strategy for non-small cell lung carcinoma. Cancer Cell 18, 63–73 (2010).
  Article CAS PubMed Google Scholar
• Haigis, K.M. et al. Differential effects of oncogenic K-Ras and N-Ras on proliferation, differentiation and tumor progression in the colon. Nat. Genet. 40, 600–608 (2008).
  Article CAS PubMed PubMed Central Google Scholar
• Adjei, A.A. et al. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J. Clin. Oncol. 26, 2139–2146 (2008).
  Article CAS PubMed Google Scholar
• Schwartz, G.K. et al. Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1). Br. J. Cancer 104, 1862–1868 (2011).
  Article CAS PubMed PubMed Central Google Scholar
• Paweletz, C.P. et al. Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front. Oncogene 20, 1981–1989 (2001).
  Article CAS PubMed Google Scholar
• Serrano, M. et al. Role of the INK4a locus in tumor suppression and cell mortality. Cell 85, 27–37 (1996).
  Article CAS PubMed Google Scholar
• Vaira, V. et al. Preclinical model of organotypic culture for pharmacodynamic profiling of human tumors. Proc. Natl. Acad. Sci. USA 107, 8352–8356 (2010).
  Article CAS PubMed PubMed Central Google Scholar
• Smyth, G.K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat. Appl. Genet. Mol. Biol. 3, Article3 (2004).
  Article Google Scholar
• Irizarry, R.A. et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249–264 (2003).
  Article PubMed Google Scholar
• Faith, J.J. et al. Large-scale mapping and validation of Escherichia coli transcriptional regulation from a compendium of expression profiles. PLoS Biol. 5, e8 (2007).
  Article PubMed PubMed Central Google Scholar
• Opsahl, T., Agneessens, F. & Skvoretz, J. Node centrality in weighted networks: Generalizing degree and shortest paths. Soc. Networks 32, 245–251 (2010).
  Article Google Scholar